Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 12,240,000 shares, an increase of 14.9% from the March 15th total of 10,650,000 shares. Based on an average trading volume of 2,340,000 shares, the days-to-cover ratio is currently 5.2 days. Approximately 9.6% of the shares of the company are short sold.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of AUPH. China Universal Asset Management Co. Ltd. increased its position in shares of Aurinia Pharmaceuticals by 95.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 1,798 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter worth approximately $30,000. Sunbelt Securities Inc. purchased a new stake in Aurinia Pharmaceuticals in the first quarter worth approximately $31,000. Tidemark LLC purchased a new stake in Aurinia Pharmaceuticals in the fourth quarter worth approximately $39,000. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Aurinia Pharmaceuticals by 54.2% during the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 1,142 shares during the period. 36.83% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the company. Royal Bank of Canada decreased their price objective on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an "outperform" rating for the company in a report on Friday, February 16th. Jefferies Financial Group reduced their target price on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a "hold" rating for the company in a report on Friday, February 16th. Cantor Fitzgerald reduced their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, March 1st. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $10.00.
Get Our Latest Stock Analysis on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Price Performance
AUPH stock traded up $0.02 during mid-day trading on Friday, reaching $5.10. 1,721,800 shares of the company traded hands, compared to its average volume of 1,338,745. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.50 and a quick ratio of 4.99. The company has a fifty day moving average price of $5.78 and a 200-day moving average price of $7.36. The company has a market capitalization of $737.55 million, a P/E ratio of -9.44 and a beta of 1.36. Aurinia Pharmaceuticals has a 52-week low of $4.85 and a 52-week high of $12.43.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The company had revenue of $45.10 million during the quarter, compared to the consensus estimate of $45.00 million. Aurinia Pharmaceuticals had a negative return on equity of 20.10% and a negative net margin of 44.45%. The firm's revenue for the quarter was up 58.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.18) earnings per share. As a group, analysts anticipate that Aurinia Pharmaceuticals will post -0.06 earnings per share for the current year.
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
